University of Kentucky Alzheimer's Disease Research Center
- Institution
- UNIVERSITY OF KENTUCKY, KY
- Principal investigator
- Linda J Van Eldik
- Funding
- $2.8M
- Duration
- 2021–2026
Moonbase score
Still being scored
Abstract
Project Summary/Abstract: Overall The University of Kentucky Alzheimer’s Disease Research Center (UK-ADRC) is an experienced and collaborative center that has facilitated pioneering research in AD and related dementias (ADRD) since its inception in 1985. Our principal mission is to serve as the focal point for all AD-related activities at UK and this region of the United States, by providing an environment and core resources that catalyze innovative research, outreach, education, and clinical programs. Our signature resources include: 1) a cognitively normal group of ~500 subjects followed longitudinally, together with ~300 additional subjects who transitioned to MCI or dementia, and all committed to brain autopsy upon death; 2) a strong autopsy program with clinical- neuropathological correlations and short postmortem interval research material; 3) a maturing program studying the early preclinical biological emergence of mixed pathologies and how they contribute to late life dementia states, with an increasing focus on antemortem biomarker collection; 4) an integrated centralized database and innovative biostatistical expertise to characterize clinical and biological transitions; 5) a successful and close partnership with the African-American community and increased participation of underrepresented individuals in our longitudinal cohort and ADRC-affiliated research studies and clinical trials; and 6) a rich, interdisciplinary training environment that provides multi-faceted educational opportunities for researchers, healthcare providers, and our community partners. The overarching theme of the UK-ADRC is: Transitions from Normal to Late-Life Multi-Etiology Dementia. Our well-characterized, longitudinal cohort and historically strong neuropathology program focused on normal aging, preclinical disease states and early cognitive transitions have been central to our success in defining early pathogenic mechanisms underlying the transitions from normal cognitive aging to impairment. In addition, these efforts have been a driving force in our recognition of the heterogeneity and multiple pathologies that characterize late-life dementia. The UK-ADRC will continue to leverage our strengths to enhance our impact and “Centerness” by our focus on this overarching theme, and the pursuit of four overall specific aims. Aim 1. Facilitate and enhance basic, translational and clinical research in AD and related dementias. Aim 2. Provide the necessary resources and interactive environment to support and create new opportunities for innovative research. Aim 3. Maintain and grow educational opportunities and community partnerships to promote awareness, increase participation in research, and provide an innovative and interdisciplinary training environment. Aim 4. Contribute to the national efforts and collaborative activities with other centers, programs and groups to advance AD/ADRD research, education, and care.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF KENTUCKY
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of KentuckyNot yet scored
Training in Translational Research in Alzheimer's and Related Dementias (TRIAD)
Michael Paul Murphy · $441K · 2022–2027
- NIH · University of KentuckyNot yet scored
Core A: University of Kentucky Alzheimer's Disease Core Center
Linda J Van Eldik · $279K · 2021–2026
- NIH · University of KentuckyNot yet scored
Core G: University of Kentucky Alzheimer's Disease Core Center
Linda J Van Eldik · $77K · 2021–2026